Some quick thoughts. This therapy uses a combination of methods that are already used in oncology. The usage of bacteria in oncology as part of immunotherapies

Some quick thoughts. This therapy uses a combination of methods that are already used in oncology. The usage of bacteria in oncology as part of immunotherapies has existed for decades via the use of BCG, although it is notably that these bacteria have genetic modifications to allow it to create a delivery vehicle as well. siRNAs have always been an attractive method but lacked proper delivery methods and initially had issues with degradation. The knockdown of DNA polymerases is new to me. Typically chemotherapeutics are anti-metabolites or seek to arrest mitosis (taxanes for example lock part of the cytoskeleton [microtubules] needed to move chromosomes). Targeting DNA polymerase makes fundamentally more sense because you would by and large avoid disrupting other cellular functions. Hopefully this represents another tool in the kit in regards to conjugate/combination therapies like Trastuzumab-deruxtecan. Quick question: Based on this statements would these therapy work particularly well against metastatic disease given its moa for cell selectivity?